21 June 2021 - - US-based life science research and clinical diagnostic products provider Bio-Rad Laboratories, Inc. (NYSE: BIO) has launched its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective tool used to detect SARS-CoV-2 in a community's wastewater, the company said.

ddPCR technology is recommended in the Centers for Disease Control and Prevention guidelines (CDC) for wastewater testing, and use of the technology has been published by the Environmental Protection Agency as a dependable method to quantify viruses in wastewater.

The PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit includes all reagents needed to detect the virus in wastewater along with software for automated analysis.

The test runs on Bio-Rad's QX200 Droplet Digital PCR System, QX200 AutoDG Droplet Digital PCR System, and the QX ONE Droplet Digital PCR System. It joins Bio-Rad's menu of COVID-19 products that are being used in the global fight against COVID-19.

Other products include molecular qPCR and ddPCR instruments and assays, antibody tests, quality controls, and ddPCR assays to detect SARS-CoV-2 variants of concern.

Bio-Rad Laboratories, Inc. (NYSE: BIO) in developing, manufacturing, and marketing a range of innovative products for the life science research and clinical diagnostic markets.

With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare.

Its customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality.

Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding USD 2.5bn in 2020.